Overall, in light of personalized therapy, this large-scale dataset analysis suggests a potential role of both YY1 and RKIP as novel two-signature biomarkers for LC, with a diagnostic as well as a prognostic significance. Here, PEBP1 is linked to laryngotracheoesophageal cleft.